These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients. Yamada Y; Ikawa K; Nakamura K; Mitsui K; Narushima M; Hibi H; Ikeda K; Morikawa N; Honda N Int J Antimicrob Agents; 2010 May; 35(5):504-6. PubMed ID: 20188521 [TBL] [Abstract][Full Text] [Related]
4. Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients. Ikawa K; Morikawa N; Matsuda S; Ikeda K; Ohge H; Takesue Y; Sueda T Int J Antimicrob Agents; 2007 Oct; 30(4):352-5. PubMed ID: 17644344 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia. Stein GE; Kulhanek G; Smith CL; Kuti JL; Nicolau DP; Scharmen A; Farnum C; Tran M; Kalra A; Havlichek DH Ann Pharmacother; 2012 Oct; 46(10):1281-6. PubMed ID: 23012385 [TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation. Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T Diagn Microbiol Infect Dis; 2008 Nov; 62(3):292-7. PubMed ID: 18703305 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. Hori T; Nakano M; Kimura Y; Murakami K In Vivo; 2006; 20(1):91-6. PubMed ID: 16433034 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients. Ikawa K; Morikawa N; Uehara S; Monden K; Yamada Y; Honda N; Kumon H Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn. Yang RH; Rong XZ; Hua R; Zhang T Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. Cirillo I; Vaccaro N; Turner K; Solanki B; Natarajan J; Redman R J Clin Pharmacol; 2009 Jul; 49(7):798-806. PubMed ID: 19553404 [TBL] [Abstract][Full Text] [Related]
12. Ceftriaxone bone penetration in patients with septic non-union of the tibia. Garazzino S; Aprato A; Baietto L; D'Avolio A; Maiello A; De Rosa FG; Aloj D; Siccardi M; Biasibetti A; Massè A; Di Perri G Int J Infect Dis; 2011 Jun; 15(6):e415-21. PubMed ID: 21497532 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit. Bhalodi AA; Keel RA; Quintiliani R; Lodise TP; Nicolau DP; Kuti JL Ann Pharmacother; 2013 May; 47(5):617-27. PubMed ID: 23585647 [TBL] [Abstract][Full Text] [Related]
20. Stability of doripenem in vitro in representative infusion solutions and infusion bags. Psathas PA; Kuzmission A; Ikeda K; Yasuo S Clin Ther; 2008 Nov; 30(11):2075-87. PubMed ID: 19108795 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]